This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Medical Instrument Stocks Head-to-Head: Abiomed vs. STERIS
by Zacks Equity Research
Here we take a look at the fundamentals of Abiomed (ABMD) and STERIS (STE) to determine which stock is a better pick in the Medical Instruments space.
Varian Medical (VAR) Launches Velocity 4.0, Shares Rise
by Zacks Equity Research
The introduction of Velocity 4.0 is in line with Varian Medical's (VAR) strategy to target the radiation-dosimetry market. The platform will help patients with liver malignancies.
Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) successful strategies to build esoteric testing business and boost profit margins raise optimism among investors on the stock.
Here's Why You Should Hold on to Varian Medical Stock Now
by Zacks Equity Research
Here we take a peek at Varian Medical's (VAR) performance to analyze why investors should hold on to this stock despite adversities.
SRDX or HAE: Which is a Better Medical Product Stock?
by Zacks Equity Research
Here we analyze the financials and fundamental factors of Haemonetics (HAE) and Surmodics (SRDX) to decide which is a better investment option.
Zacks.com featured highlights include: Abaxis, Haynes International, MakeMyTrip and Vectrus
by Zacks Equity Research
Zacks.com featured highlights include: Abaxis, Haynes International, MakeMyTrip and Vectrus
4 Top Stocks to Buy With Superb Earnings Acceleration
by Tirthankar Chakraborty
If the rate of a company's quarter-over-quarter earnings growth increases within a stipulated frame of time, it can be called earnings acceleration.
Abaxis Banks on Strong Veterinary Business Amid Margin Woes
by Zacks Equity Research
Abaxis' (ABAX) strong performance in Veterinary consumables drives growth. Weak gross and operating margin scenario is a concern.
Why Is Abaxis (ABAX) Up 6.5% Since Its Last Earnings Report?
by Zacks Equity Research
Abaxis (ABAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abaxis (ABAX) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Abaxis (ABAX) rides high on recently received approval from USDA.
Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Abaxis (ABAX) Q3 earnings gain on strength in Medical and Veterinary segments.
Abaxis' Product Line Expansion Aids Growth, Rivalry Rife
by Zacks Equity Research
Abaxis' (ABAX) growing portfolio of rapid test menu and a strong performance in Veterinary consumables drive growth. Intense competition in both the Medical and Veterinary markets is a concern.
Abaxis' (ABAX) Preliminary Results for Q3 Cheer Investors
by Zacks Equity Research
Abaxis (ABAX) expects substantial tax savings from the recent U.S. tax reform.
Abaxis Well Poised on Solid Prospects, Competition Rife
by Zacks Equity Research
Abaxis' (ABAX) new sales and marketing strategies boost investors' confidence.
New Strong Sell Stocks for December 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
ABAXIS (ABAX) Up 6.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
ABAXIS (ABAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abaxis (ABAX) Posts In-Line Earnings in Q2, Lags Revenues
by Zacks Equity Research
Abaxis (ABAX) misses the Zacks Consensus Estimate for revenues due to softness in the medical market in Q2. Weak margins are a concern as well.
New Strong Sell Stocks for September 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for August 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
What Falling Estimates & Price Mean for Abaxis (ABAX)
by Zacks Equity Research
Abaxis (ABAX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
New Strong Sell Stocks for August 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Abaxis (ABAX) Misses Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Despite Abaxis' lackluster performance in the fiscal first quarter, its new marketing strategies and recent launches buoy optimism.
Medical Product Stocks' Earnings on Jul 20: ABT, ISRG & More
by Zacks Equity Research
The market remained jittery towards medical space due to uncertainties surrounding the future of the healthcare act.
Abaxis (ABAX) Product Portfolio Strong, Competition Rife
by Zacks Equity Research
On Jun 28, we issued an updated research report on California-based Abaxis, Inc. (ABAX).
New Strong Sell Stocks for May 2nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: